Clopidogrel is an oral antiplatelet agent (thienopyridine class) to inhibit blood clots in coronary artery disease, peripheral vascular disease, and cerebrovascular disease.
In patients who have had a minor stroke or a transient ischemic stroke (TIA), the risk of getting a full-blown stroke or a major stroke is high. A new study has found that these high-risk individuals, when prescribed with clot-preventing drugs clopidogrel along with aspirin show a lower risk of getting major stroke.
Results from an international clinical trial of more than 4880 participants, published in the New England Journal of Medicine, show that combining clopidogrel and aspirin following a small stroke or experiencing minor stroke symptoms decreases risk of a new stroke, heart attack or other ischemic event within 90 days.
The research was part of the Platelet-Oriented Inhibition in New TIA and minor ischemic stroke trial -- a randomized, double-blind, placebo-controlled trial conducted between May 2010 and December 2017.
Using genetic testing to inform which blood thinner to use following a procedure to open narrowed blood vessels resulted in significantly fewer complications among patients, according to new research in Circulation: Genomic and Precision Medicine, an American Heart Association journal.
The combined rate of death from any cause, heart attack or stroke within 18 months was not significantly different in patients with acute coronary syndrome who were randomly assigned to receive dual antiplatelet therapy for either six months or at least 12 months after receiving a drug-eluting stent.
Using just two anticlotting medicines for patients who have atrial fibrillation and have had a stent placed in a heart artery is safer than using the current standard treatment of three medications, according to a new study presented by Brigham and Women's Hospital cardiologist Christopher Cannon, MD, at the European Society of Cardiology and published simultaneously in The New England Journal of Medicine.
The first ESC Focused Update on Dual Antiplatelet Therapy in Coronary Artery Disease is published online today in European Heart Journal, and on the ESC website.
A new scoring method may help predict who is at high risk of serious bleeding after a stroke, according to a study published in the August 2, 2017, online issue of Neurology, the medical journal of the American Academy of Neurology.
Findings from a large, community-based study show that antithrombotic therapy doesn't decrease low-risk atrial fibrillation patients' risk of suffering a stroke within five years. In fact, researchers found that low-risk patients fared better without any antithrombotic therapy.
The University of Maryland Medical Center is now offering a simple genetic test to patients who receive heart stents to determine whether they have a genetic deficiency that affects how they respond to a common drug to prevent blood clots.
Heart care in France ranks 1st among 30 measured countries, says the Euro Heart Index 2016 (EHI), published today in Brussels. The Index compares heart care in 30 European countries, with France the champion, closely followed by Norway and Sweden.
New guidelines for the treatment of peripheral artery disease (PAD), include recommendations on the use of antiplatelet therapy to reduce the risk of blood clots and statin drugs to lower cholesterol and advise PAD patients to participate in a structured exercise program.
The American College of Cardiology's National Cardiovascular Data Registry was the source of data for research published throughout 2016, including a study examining if atrial fibrillation patients are being prescribed oral anticoagulants, how appropriate use criteria correlates to angioplasty rates and the variation among racial groups for revascularization procedures.
A short-term course of dual antiplatelet therapy (DAPT) is non-inferior to a longer course in patients who have undergone placement of a particular kind of drug-eluting stent (DES), researchers reported here.
Which antiplatelet medication is best after a coronary stent? The Tailored Antiplatelet Therapy to Lessen Outcomes After Percutaneous Coronary Intervention (TAILOR-PCI) Study examines whether prescribing heart medication based on a patient's CYP2C19 genotype will help prevent heart attack, stroke, unstable angina, and cardiovascular death in patients who undergo percutaneous coronary intervention (PCI), commonly called angioplasty.
Researchers demonstrate a means of gauging the effects of drugs tested in randomised trials in real-world patients.
The first look at CYP2C19 mutations in the context of a randomised controlled trial has confirmed suspicions that they affect the efficacy of clopidogrel in patients with acute stroke.
Doctors worried about dangerous blood clots in patients undergoing a coronary artery procedure— such as angioplasty to treat a heart attack — will often administer antiplatelet therapy to head off complications.
Women younger than 55 years of age who undergo percutaneous coronary intervention (PCI) for acute coronary syndrome (ACS) are more likely to experience one-year adverse cardiovascular events due to risk factors such as diabetes and chronic kidney disease, yet they are less likely to receive potent antiplatelet therapy than men. The PROMETHEUS study found that outcomes for both men and women post-PCI are dependent on their baseline risk factors, not their sex.
Patients who go to UPMC Presbyterian for heart catheterization and who receive a stent to treat clogged arteries are now being screened with a simple blood test to determine if they have a gene variant that makes them less likely to respond to a blood-thinning medication commonly prescribed after the procedure.